Progressive Labs SAMe-200 is an enteric coated tablet containing 200 mg of S-adenosyl-methionine. S-adenosyl-l-methionine (SAMe) is an important biological agent in the human body, participating in over 40 essential biochemical reactions.
SAMe is normally produced in the liver from the amino acid methionine which is abundant in most diets. Folic acid and vitamin B12 are necessary for the synthesis of SAMe, and deficiencies of these vitamins results in low concentrations of SAMe in the central nervous system. Low blood or central nervous system levels of SAMe have been detected in people with cirrhosis of the
liver, coronary heart disease, Alzheimer’s disease, and depression.
SAMe functions as a methyl group donor in reaction catalyzed by methyltransferase enzymes. SAMe also serves as a precursor molecule for glutathione synthesis.‡
SAMe-200 is in an enteric coated tablet to allow for disintegration and optimal absorption in the intestinal tract.
Our SAMe-200 provides 200 mg SAMe (s-adenosyl-l-methionine) per enteric coated tablet. SAMe provides nutritional support for joints, liver and gallbladder, mood, and mental function.‡
Warning: Individuals being treated for neurological conditions should consult their health care practitioner before using this product. Individuals with bipolar (manic) depression should take SAMe only under professional medical supervision.
Warning: If you are pregnant or lactating woman, have any health conditions, or are taking any medication, make sure to consult your healthcare provider prior to use.
‡ These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure or prevent any disease.
One tablet daily, on an empty stomach.
30 Enteric Coated Tablets
De Silva V, El-Metwally A, Ernst E, Lewith G, Macfarlane GJ; Arthritis Research UK Working Group on Complementary and Alternative Medicines. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology (Oxford). 2011 May;50(5):911-20. doi: 10.1093/rheumatology/keq379. Epub 2010 Dec 17. PMID: 21169345.
Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012 Oct;92(4):1515-42. doi: 10.1152/physrev.00047.2011. PMID: 23073625; PMCID: PMC3698976.
Rutjes AW, Nüesch E, Reichenbach S, Jüni P. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007321. doi: 10.1002/14651858.CD007321.pub2. PMID: 19821403; PMCID: PMC7061276.
Cuomo A, Beccarini Crescenzi B, Bolognesi S, Goracci A, Koukouna D, Rossi R, Fagiolini A. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Ann Gen Psychiatry. 2020 Sep 5;19:50. doi: 10.1186/s12991-020-00298-z. PMID: 32939220; PMCID: PMC7487540.
Diego Dolcetta, Pietro Parmigiani, Luigi Salmaso, Roberta Bernardelle, Ugo Cesari, Gilberto Andrighetto, Giuseppe Baschirotto, William L. Nyhan & Uros Hladnik (2013) Quantitative Evaluation of the Clinical Effects of S-Adenosylmethionine on Mood and Behavior in Lesch-Nyhan Patients, Nucleosides, Nucleotides & Nucleic Acids, 32:4, 174-188, DOI: 10.1080/15257770.2013.774012
Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle P. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ). 2003 Aug;(64):1-3. PMID: 12899148; PMCID: PMC4781303.
Cowley G, Underwood A. What is SAMe? S-Adenosylmethionine. Newsweek. 1999 Jul 5;134(1):46-50. PMID: 10538206.
Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002 Nov;76(5):1158S-61S. doi: 10.1093/ajcn/76/5.1158S. PMID: 12420702.